UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the date of March 9, 2020
Commission File Number 001-39124
Centogene N.V.
(Translation of registrant's name into English)
Am
Strande 7
18055 Rostock
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Centogene N.V.
On March 9, 2020, Centogene N.V. issued a press release titled “CENTOGENE Announces Departure of Dirk Ehlers from Executive Board”.
A copy of the press release is attached hereto as Exhibit 99.1.
2
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CENTOGENE N.V. | ||||
| Date: March 9, 2020 | ||||
| By: | /s/ Richard Stoffelen | |||
| Name: | Richard Stoffelen | |||
| Title: | Chief Financial Officer | |||
3
Exhibit Index
| Exhibit | Description of Exhibit |
| 99.1 | Press release dated March 9, 2020 |
4
Exhibit 99.1
CENTOGENE Announces Departure of Dirk Ehlers From Executive Board
Cambridge, MA, USA & Rostock/Berlin, Germany, March 9, 2020 – CENTOGENE (Nasdaq: CNTG) ─ The Company today announced that Dr. Dirk H. Ehlers, COO and President of its Clinical Diagnostics Division, has decided to step down from his role after the Annual General Meeting in June 2020 and leave the Company for personal reasons. He has been part of the Executive Management Board for the past two years and helped to lead the Company through a period of strong growth and the public listing of its shares on NASDAQ in November 2019.
Prof. Dr. Arndt Rolfs, CEO of the Company, stated, “We want to thank Dirk for his significant contributions to CENTOGENE and wish him well.” His successor will be announced in due course.
###
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data and innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 2.1 billion weighted data points from approximately 500,000 patients representing over 120 different countries as of December 31, 2019, or an average of approximately 600 data points per patient.
The Company’s platform includes epidemiologic, phenotypic and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of December 31, 2019, the Company collaborated with over 35 pharmaceutical partners for over 40 different rare diseases.
Media Contact:
CENTOGENE
Ben Legg
Corporate Communications
press@centogene.com
FTI Consulting
Bridie Lawlor
+1.917.929.5684
bridie.lawlor@fticonsulting.com